scholarly journals Small molecule target identification using photo-affinity chromatography

Author(s):  
Seung-Yong Seo ◽  
Timothy W. Corson
2017 ◽  
Author(s):  
Neel S. Madhukar ◽  
Prashant K. Khade ◽  
Linda Huang ◽  
Kaitlyn Gayvert ◽  
Giuseppe Galletti ◽  
...  

AbstractDrug target identification is one of the most important aspects of pre-clinical development yet it is also among the most complex, labor-intensive, and costly. This represents a major issue, as lack of proper target identification can be detrimental in determining the clinical application of a bioactive small molecule. To improve target identification, we developed BANDIT, a novel paradigm that integrates multiple data types within a Bayesian machine-learning framework to predict the targets and mechanisms for small molecules with unprecedented accuracy and versatility. Using only public data BANDIT achieved an accuracy of approximately 90% over 2000 different small molecules – substantially better than any other published target identification platform. We applied BANDIT to a library of small molecules with no known targets and generated ∼4,000 novel molecule-target predictions. From this set we identified and experimentally validated a set of novel microtubule inhibitors, including three with activity on cancer cells resistant to clinically used anti-microtubule therapies. We next applied BANDIT to ONC201 – an active anti- cancer small molecule in clinical development – whose target has remained elusive since its discovery in 2009. BANDIT identified dopamine receptor 2 as the unexpected target of ONC201, a prediction that we experimentally validated. Not only does this open the door for clinical trials focused on target-based selection of patient populations, but it also represents a novel way to target GPCRs in cancer. Additionally, BANDIT identified previously undocumented connections between approved drugs with disparate indications, shedding light onto previously unexplained clinical observations and suggesting new uses of marketed drugs. Overall, BANDIT represents an efficient and highly accurate platform that can be used as a resource to accelerate drug discovery and direct the clinical application of small molecule therapeutics with improved precision.


2020 ◽  
Vol 28 ◽  
pp. S489-S490
Author(s):  
Y. Sun ◽  
D. Chan ◽  
K. Cheung ◽  
V. Leung

2018 ◽  
Vol 54 (70) ◽  
pp. 9833-9836 ◽  
Author(s):  
Thomas F. Gronauer ◽  
Melanie M. Mandl ◽  
Markus Lakemeyer ◽  
Mathias W. Hackl ◽  
Martina Meßner ◽  
...  

To expedite functional studies of human ClpP we introduce tailored small molecule inhibitors. These compounds are active against the proteolytic ClpXP complex. Target identification elucidates anti-proliferative effects against cancer cells.


2011 ◽  
Vol 1218 (29) ◽  
pp. 4649-4659 ◽  
Author(s):  
Marc Arnold ◽  
Holger Bittermann ◽  
Bernd Kalbfuss-Zimmermann ◽  
Thomas Neumann ◽  
Kristina Schmidt ◽  
...  

The Analyst ◽  
2016 ◽  
Vol 141 (24) ◽  
pp. 6571-6582 ◽  
Author(s):  
Nur Mustafaoglu ◽  
Tanyel Kiziltepe ◽  
Basar Bilgicer

m-NBST is a small-molecule based membrane affinity chromatography system that utilizes the NBS, providing high levels of antibody recovery and purity.


2020 ◽  
Author(s):  
Zhongyang Liu ◽  
Honglei Li ◽  
Zhaoyu Jin ◽  
Yang Li ◽  
Feifei Guo ◽  
...  

AbstractMotivationProtein and peptide drugs, after decades of development have grown into a major drug class of the marketplace. Target identification and validation is crucial for their discovery, and bioinformatics estimation of candidate targets based on characteristics of successful target proteins will help improve efficiency and success rate of target selection. However, owing to the development history of the pharmaceutical industry, previous systematic exploration of target space mainly focused on traditional small-molecule drugs, whereas that for protein and peptide drugs is blank. Here we systematically explored target spaces in the human genome specially for protein and peptide drugs.ResultsWe found that compared with other proteins, targets of both successful protein and peptide drugs have their own characteristics in many aspects and are also significantly different from those of traditional small-molecule drugs. Further based on these features, we developed effective genome-wide target estimation models respectively for protein and peptide drugs.


Sign in / Sign up

Export Citation Format

Share Document